Summary
Updated Aug 30, 2026
Sandesh Seth is Chief Executive Officer, Director of Actinium Pharmaceuticals, Inc. (ATNM). 1 SEC Form 4 filing on record, dated 18 August 2025.
Recent Transactions
1Every recent SEC Form 4 transaction Sandesh Seth has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Sandesh Seth's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- J.H. Whitney Equity Partners VII, LLC - $319.15M of AVAH open-market activity in the last 12 months
- General Atlantic (ALN HLTH), L.P. - $315.49M of ALHC open-market activity in the last 12 months
- GENERAL ATLANTIC, L.P. - $315.49M of ALHC open-market activity in the last 12 months
- Fairmount Funds Management LLC - $300.01M of ORKA open-market activity in the last 12 months
- August J. Troendle - $249.99M of MEDP open-market activity in the last 12 months
- A/S Genmab - $234.86M of MRUS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Sandesh Seth?
Sandesh Seth is a corporate insider, tracked as Chief Executive Officer, Director of Actinium Pharmaceuticals, Inc. (ATNM). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Sandesh Seth last file a Form 4?
The only primary Form 4 on record is dated 18 August 2025.
Where can I see all of Sandesh Seth's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Sandesh Seth and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
